{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:00Z","timestamp":1789092420870,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"All India Institute of Medical Sciences New Delhi","award":["F.8.AC-36\/2021\/RS"],"award-info":[{"award-number":["F.8.AC-36\/2021\/RS"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Radioactive iodine (RAI) therapy is the standard-of-care for metastatic differentiated thyroid cancer (DTC), but ~60% of patients show resistance before achieving satisfactory response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eligible patients were randomly assigned to RAI therapy plus lenvatinib (RAI-L arm) or standard RAI therapy alone (RAI arm). All patients were administered RAI therapy (5.5\u20137.4\u00a0GBq) every 6\u20139 months, and patients in RAI-L arm were additionally administered lenvatinib (10\u00a0mg once daily). The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival, quality of life, and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fifty patients were enrolled (mean age 49.1\u00b112.6\u00a0y, range 21\u201367). ORR was significantly higher in the RAI-L arm compared with RAI arm (54.5% vs. 24%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.03). Subgroup analysis indicated combination therapy was more beneficial in age older than or equal to 55 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.04), follicular thyroid carcinoma (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.04), presence of both pulmonary and extra-pulmonary metastases (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.007), and RAI therapy-naive (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02) patients. Median PFS in the RAI-L arm was 36 months (95% CI: 24.5\u201347.5) versus 26 months (95% CI: 18.9\u201333.1) in the RAI arm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.09). Grade \u22653 adverse events were more frequent in the RAI-L arm (45.5%) compared with RAI arm (8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.006), with hypertension (31.8%) and hand-foot skin reaction (13.6%) being the most common.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Combining RAI therapy with lenvatinib improved ORR with clinically meaningful prolongation of PFS; however, it comes with a burden of treatment-related toxicity, underscoring the need for careful patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006146","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T21:00:20Z","timestamp":1759179620000},"page":"e11-e18","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-9579","authenticated-orcid":false,"given":"Chandra Teja Reddy","family":"Singareddy","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-6644","authenticated-orcid":false,"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal Ramesh","family":"Chandekar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ballal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"6 Suppl","key":"R1-20251210","first-page":"3","article-title":"New and old knowledge on differentiated thyroid cancer epidemiology and risk factors","volume":"35","author":"Agate","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"R3-20251210","doi-asserted-by":"crossref","first-page":"618985","DOI":"10.1155\/2012\/618985","article-title":"Differentiated thyroid cancer: management of patients with radioiodine non responsive disease","volume":"2012","author":"Busaidy","year":"2012","journal-title":"J Thyroid Res"},{"key":"R4-20251210","doi-asserted-by":"crossref","first-page":"924841","DOI":"10.3389\/fendo.2022.924841","article-title":"Theranostic options for radioiodine refractory differentiated thyroid carcinoma: recent advances, challenges, and road ahead","volume":"13","author":"Satapathy","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R5-20251210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1308\/rcsann.2016.0300","article-title":"Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation","volume":"99","author":"Parameswaran","year":"2017","journal-title":"Ann R Coll Surg Engl"},{"key":"R6-20251210","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.3390\/ijms23179872","article-title":"Efficacy of combination therapy with lenvatinib and radioactive iodine in thyroid cancer preclinical model","volume":"23","author":"Suzuki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R7-20251210","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20251210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24020","article-title":"Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation","volume":"24","author":"Fleeman","year":"2020","journal-title":"Health Technol Assess"},{"key":"R9-20251210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"key":"R10-20251210","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/modpathol.2008.10","article-title":"Thyroid carcinoma: molecular pathways and therapeutic targets","volume":"21","author":"Nikiforov","year":"2008","journal-title":"Mod Pathol"},{"key":"R11-20251210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17460441.2020.1674280","article-title":"Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application","volume":"15","author":"Paragliola","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"R12-20251210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R13-20251210","doi-asserted-by":"crossref","first-page":"e2120","DOI":"10.1210\/clinem\/dgae024","article-title":"Optimal cumulative I-131 activity in metastatic differentiated thyroid cancer: balancing efficacy and adverse events","volume":"109","author":"Bharadwaj","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20251210","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"R15-20251210","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","article-title":"Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set","volume":"25","author":"Jyani","year":"2022","journal-title":"Value Health"},{"key":"R16-20251210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","article-title":"The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency","volume":"65","author":"Sim","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"R17-20251210","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/BF00353775","article-title":"Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine","volume":"18","author":"Pacini","year":"1994","journal-title":"World J Surg"},{"key":"R18-20251210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/cen.12558","article-title":"Lung metastases from differentiated thyroid carcinoma: prognostic factors related to remission and disease-free survival","volume":"82","author":"Chopra","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R19-20251210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/thy.2012.0654","article-title":"Long-term prognosis of differentiated thyroid cancer with lung metastasis in korea and its prognostic factors","volume":"24","author":"Cho","year":"2014","journal-title":"Thyroid"},{"key":"R21-20251210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"R23-20251210","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12957-019-1626-4","article-title":"Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review","volume":"17","author":"Sheu","year":"2019","journal-title":"World J Surg Oncol"},{"key":"R24-20251210","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-019-04499-x","article-title":"Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"47","author":"Adant","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20251210","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"R26-20251210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10456-015-9476-3","article-title":"Combining radiotherapy with sunitinib: lessons (to be) learned","volume":"18","author":"Kleibeuker","year":"2015","journal-title":"Angiogenesis"},{"key":"R27-20251210","doi-asserted-by":"crossref","first-page":"112390","DOI":"10.1016\/j.yexcr.2020.112390","article-title":"Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor","volume":"398","author":"Suzuki","year":"2021","journal-title":"Exp Cell Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:00:39Z","timestamp":1765371639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006146"}},"subtitle":["A Pilot Study"],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006146","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"2025-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}